Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285628 | 0.81 | HCAR2 (0.39) | MTNR1AMTNR1BALDH1A1POLBMAPK1 | |
| SCHEMBL914115 | 0.77 | MTNR1A (0.49) | ELANEMTNR1AMTNR1BALDH1A1FFAR1 | |
| SCHEMBL285591 | 0.76 | TDP1 (0.41) | ELANEMTNR1AMTNR1BATMTDP1 | |
| SCHEMBL718998 | 0.75 | ALDH1A1 (0.39) | MTNR1AMTNR1BALDH1A1HPGDPOLB | |
| SCHEMBL41864 | 0.74 | HCAR2 (0.53) | ELANEATMALDH1A1HPGDHCAR2 | |
| SCHEMBL10907558 | 0.74 | HCAR2 (0.53) | ELANEATMALDH1A1HPGDHCAR2 | |
| SCHEMBL285609 | 0.73 | MTNR1A (0.36) | ELANEMTNR1AMTNR1BALDH1A1MAPT | |
| SCHEMBL285265 | 0.73 | TDP1 (0.47) | ELANEMTNR1AMTNR1BTDP1ALDH1A1 | |
| SCHEMBL719131 | 0.72 | TDP1 (0.49) | ELANETDP1ALDH1A1POLB | |
| SCHEMBL285167 | 0.72 | TDP1 (0.49) | ELANETDP1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | ELANE 4130/4885MTNR1A 4207/4885MTNR1B 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.